Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeutics Phase 1 single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous and intravenous SAB01 in healthy adults ALAMEDA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Santa Ana Bio, a precision immunology company developing targeted […]
\